Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
10.3881/j.issn.1000-503X.2017.04.016
- VernacularTitle:吉西他滨联合替吉奥治疗晚期胰腺癌的疗效分析
- Author:
Yue-Juan CHENG
1
;
Chang-Ting MENG
1
;
Ya-Juan SHAO
1
;
Ning-Ning LI
1
;
Na ZHOU
1
;
Xiao-Yan YAN
2
;
Xin GAO
3
;
Jian-Feng ZHOU
1
;
Chun-Mei BAI
1
Author Information
1. Department of Medical Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
2. Department of Biostatistics,Peking University Clinical Research Institute,Beijing 100191,China.
3. Department of Radiology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- From:
Acta Academiae Medicinae Sinicae
2017;39(4):562-567
- CountryChina
- Language:English
-
Abstract:
Objective To explore the efficacy and toxicities of gemcitabine combined with S-1 in treating locally advanced and metastatic pancreatic ductal adenocarcinoma and prognostic factors. Methods We retrospectively analyzed the clinical data of patients with locally advanced and metastatic pancreatic cancer receiving gemcitabine and S-1 as first-line therapy in the Department of Medical Oncology,Peking Union Medical College Hospital from January 2014 to January 2017.Gemcitabine was administered at a dose of 1000 mg/mover 30 min-utes on days 1 and 8,and oral S-1 at a dose of 40-60 mg twice daily from days 1 to 14,repeated every 3 weeks.All patients received at least two cycles of chemotherapy. Results A total of 60 patients were included,13(22%) achieved partial remission,37(61%) had stable disease,and 10(17%) experienced progressive disease.The median progression-free survival was 7 months(95% CI=6-10 months) and the median overall survival was 12 months(95% CI=9-20 months).Both univariate and multivariate analyses of prognostic factors showed primary resection was significant in predicting shorter progression-free survival and lung metastasis was significant for shorter overall survival.The most common grade 3-4 toxicities were neutropenia(27%) and leukopenia(18%). Conclusion Gemcitabine combined with S-1 is an effective regimen with manageable toxicities in the treatment of advanced pancreatic cancer and can be used as first-line therapy.
